Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 36Colorectal Neoplasms 17Small Cell Lung Carcinoma 8Neoplasms 8Stomach Neoplasms 7Neoplasm Metastasis 5Sarcoma, Ewing 4Rhabdomyosarcoma 4Recurrence 4Osteosarcoma 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Ovarian Neoplasms 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Solid Tumor 2Neuroblastoma 2Nasopharyngeal Carcinoma 2Metastatic Pancreatic Adenocarcinoma 2Head and Neck Neoplasms 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Wilms Tumor 1Weight Loss 1Somatostatinoma 1Solid Tumor Cancer 1Small Cell Lung Cancer Extensive Stage 1

Interventions

Capecitabine 2irinotecan sucrosofate 1Immunotherapy 1Folfox protocol 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Rectal Cancer × irinotecan sucrosofate × Clear all
NCT07281157 2026-06-03

Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡